Depression Outpatient Cardiology Screening Study

Overview

This study compares the effects of depression screening and case management to usual care in cardiology outpatients with documented evidence of coronary heart disease. Despite strong evidence that depression is a risk factor for cardiac events, there is insufficient evidence to support the use of depression screening in cardiac patients.

Full Title of Study: “Randomized Controlled Trial of Screening for Depression in Cardiac Outpatients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: July 2016

Detailed Description

Depression and cardiovascular disease are highly comorbid, and depression is a risk factor for psychosocial morbidity, poor adherence to medical treatment regimens, physical inactivity, poor physical functioning, and medical morbidity and mortality in cardiac patients, especially following an acute coronary syndrome (ACS). The American Heart Association recently recommended that all cardiac patients be screened for depression in order to improve identification and treatment of this risk factor. Patients are screened for depression during an outpatient cardiology visit and those that screen positive will be contacted for enrollment into this study. Patients are then randomized to receive collaborative care involving the patient, the patient's primary care physician (PCP), the cardiologist and the nurse case manager, or usual care (the patient is informed he/she screened positive for depression and is advised to contact their PCP and/or cardiologist). The PCP and/or cardiologist are free to evaluate, treat and refer that patient to mental health services as they deem necessary. Patients in both groups will be monitored for depression severity and duration at 3, 6 and 12 months after enrollment. The course of their depression since enrollment or last follow-up includes remissions, new onsets, relapses, recurrences, and treatment will be determined.

Interventions

  • Behavioral: Collaborative Care
    • No direct treatment will be offered. We will make treatment recommendations to the patient, PCP and cardiologist. Referral to mental health specialist is also possible, depending on need. The nurse case manager will monitor treatment progress and patient status for duration of the intervention period.

Arms, Groups and Cohorts

  • No Intervention: Usual Care (UC)
    • Patients will receive only the care provided by their primary care physicians or other medical professionals outside of the study.
  • Experimental: Collaborative Care (CC)
    • Patients randomized to the Collaborate Care (CC) arm of this study will receive brief screening, consultative, and referral services. This collaborative approach includes the patient, the patient’s PCP, the cardiologist, and the nurse case manager (NCM), using evidence based recommendations for depression treatment and follow-up care.

Clinical Trial Outcome Measures

Primary Measures

  • Beck Depression Inventory 2
    • Time Frame: 12 months
    • Self report depression symptom inventory. Scale ranges from 0-63. The higher the score the more depression symptoms. A score of 12 or greater is considered to indicate a clinically significant depression.

Secondary Measures

  • Treatment Satisfaction Scale.
    • Time Frame: 12 months
    • This one item scale asks patients to rate their satisfaction with their depression treatment on a one (very dissatisfied) to 5 (very satisfied) scale.
  • PROMIS Physical Functioning Scale 10a Short Form
    • Time Frame: 12 months
    • This is a 10 item questionnaire that assesses the respondent’s ability to perform common physical activities as rated on a 1-5 scale. The total score is converted to a T score which expresses where the individual ranks relative to the reference group.

Participating in This Clinical Trial

Inclusion Criteria

  • recent history of Acute Coronary Syndrome or other cardiac event or documented heart disease – score of 10 or higher on the Patient Health Questionnaire Exclusion Criteria:

  • suicidal ideation or behavior – cognitive impairment or inability to read or speak English – schizophrenia, bipolar disorder – active substance abuse or alcoholism – severe valvular disease, severe congestive heart failure, malignancy – physical limitations that would interfere with participation in the study – medical contraindications to the use of available antidepressants – participation in a competing research protocol – physician or patient refusal

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Washington University School of Medicine
  • Collaborator
    • Agency for Healthcare Research and Quality (AHRQ)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Robert Carney, Professor of Psychiatry – Washington University School of Medicine
  • Overall Official(s)
    • Robert M. Carney, PhD, Principal Investigator, Washington University School of Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.